How could the neuroplasticity process explain the therapeutic benefit of psychedelics, and what does it mean for clinical research? How can you use a fully integrated system of care to reduce the risks to the patient of engaging in a psychedelic trial? What do the current limitations of regulatory guidance on psychedelics in trials mean for their clinical development?
Find the answers to these questions and more on how to execute psychedelic trials:
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
